Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Monthly dosing of atacicept in IgA nephropathy
2025-521519-37-00Phase 2Authorised
- Sponsor
- Vera Therapeutics
- Start
- Sep 2025
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 10
01
Overview
Phase 2 trial of atacicept in IgA nephropathy (IgAN) and renal and urinary disorders, sponsored by Vera Therapeutics. Primary endpoint: Gd-IgA1 levels through Week 24. Planned start Sep 2025; status: authorised.
02
Drugs
atacicept
03
Conditions
IgA nephropathy (IgAN)renal and urinary disorders
Beyond the preview
Go deeper on 2025-521519-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521519-37-00.